TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06492915
Drug: Gemcitabine Injection
Normalized name: gemcitabine Injection
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle
Study: NCT06411210
Drug: Semaglutide Pen Injector
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Escalated to 2.4mg or max tolerated dose
Study: NCT05512377
Drug: brigimadlin
Normalized name: Brigimadlin
DrugBank: Brigimadlin (DB18578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: brigimadlin
Study: NCT06095713
Drug: Pegunigalsidase-alfa
Normalized name: Pegunigalsidase alfa
DrugBank: Pegunigalsidase alfa (DB14992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care
Study: NCT05856695
Drug: Carboplatin + Paclitaxel + Durvalumab
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal
Study: NCT05483010
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin is commercially available.
Study: NCT04939090
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04939090
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04766047
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of dexmedetomidine intraoperatively
Study: NCT05520775
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide (subcutaneous)
Study: NCT06525220
Drug: Petosemtamab
Normalized name: Petosemtamab
DrugBank: Petosemtamab (DB18948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCLA-158
Study: NCT06525220
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Humanized Antibody
Study: NCT04744116
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05460507
Drug: Retreatment Rhenium Liposome
Normalized name: rhenium
DrugBank: Rhenium re-186 (DB19266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the CED catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
Study: NCT05183126
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion. All other doses administered as a 1-hour infusion for a total of 12 weekly doses.
Study: NCT05183126
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly intravenous (IV) infusion of a standard dose of paclitaxel 80 mg/m\^2. Dose 1 is a 90-minute infusion.~During doses 2-12, patients with low SMA will receive one 2-hour infusion and patients with sarcopenic SMA will receive one 3-hour infusion. All other doses during weeks 2-12 are standard infusion time.
Study: NCT04544189
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg (oral) once daily, in a 28-day cycle
Study: NCT04544189
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg (intramuscular, as two 250mg/5 mL injections) on Day 1 and 15 of Cycle 1 and on Day 1 of every Cycle thereafter
Study: NCT06575699
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 133 mg liposomal bupivacaine per side for rectus sheath block
Study: NCT06575699
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL bupivacaine 0.25% per side for rectus sheath block
Study: NCT06575699
Drug: Bupivacaine-Hydromorphone Cassette
Normalized name: Bupivacaine-Hydromorphone Cassette
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
Study: NCT04284839
Drug: DOAC
Normalized name: Benzamidoacetic acid
DrugBank: Robinia pseudoacacia pollen (DB10474)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
Study: NCT04284839
Drug: VKA
Normalized name: METHYLPHENIDATE HCL (AVKARE) 18MG SA TAB
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
Study: NCT04746235
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04950049
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: receive 2ml dexamethasone (5mg/ml)
Study: NCT00035061
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05657132
Drug: herbal intracanal medication paste
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: study the effect of costus herbal paste on enterococcus faecalis bacteria
Study: NCT06304597
Drug: Imfinzi
Normalized name: Imfinzi
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab is labeled to IRDye-680LT and will be administered in combination with fluorescently labelled nivolumab (Opdivo)
Study: NCT06304597
Drug: Opdivo
Normalized name: Opdivo
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is labeled to IRDye-800CW and will be administered in combination with fluorescently labelled durvalumab (Imfinzi)
Study: NCT00000647
Drug: CD4-IgG
Normalized name: Human IGG
DrugBank: Recombinant human CD4 immunoglobulin G (DB17812)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000647
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000647
Drug: Interferon alfa-n1
Normalized name: interferon alfa-n1
DrugBank: Interferon alfa-n1 (DB00011)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04160910
Drug: 5-Hydroxytryptophan
Normalized name: 5-Hydroxytryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double blinded placebo controlled. 28 day dosing period followed by 3 week washout period. Then crossover to other arm of study
Study: NCT06534983
Drug: Autogene Cevumeran
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogene cevumeran will be administered as an IV infusion per the schedule in the specified arm.
Study: NCT06534983
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered as an IV infusion per the schedule in the specified arm.
Study: NCT06534983
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution for intravenous infusion
Study: NCT06086522
Drug: QN-302
Normalized name: QN-302
DrugBank: QN-302 (DB18156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1 dose-finding study, the study design is for QN-302 to be given once a week, intravenously over 60 min, on Day 1, Day 8, and Day 15 of a 28-Day cycle.
Study: NCT05106153
Drug: Suvorexant
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant will be administered orally as per assigned treatment sequence.
Study: NCT05106153
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem will be administered orally as per assigned treatment sequence.
Study: NCT06008106
Drug: tunlametinib
Normalized name: Tunlametinib
DrugBank: Tunlametinib (DB18791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12mg BID
Study: NCT06008106
Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: according to investigators' suggestion
Study: NCT05106153
Drug: Seltorexant
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seltorexant will be administered orally as per assigned treatment sequence.
Study: NCT04524000
Drug: Alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \[Part 1\] Alpelisib administered at 200 mg (DL 1), 250 mg (DL 2) or 300mg (DL 3) orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.~If DL 1 is tolerated, the alpelisib doses of 250 mg will be investigated. If DL 2 is tolerated, the alpelisib doses of 300 mg will be investigated.~\[Part 2\] In the Part 2, participants will be enrolled into Cohort 2 (CDK4/6 inhibitor naive) and Cohort 3 (CDK4/6 inhibitor pre-treated) in parallel and alpelisib will be administered at the recommended dose identified in Part 1.
Study: NCT04524000
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant is administered at a dose of 500 mg intramuscular on Cycle 1 Day 1, Day 15, and Day 1 of every cycle thereafter (where a cycle is 28 days).
Study: NCT06414759
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily.
Study: NCT06414759
Drug: Metolazone
Normalized name: Metolazone
DrugBank: Metolazone (DB00524)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily.
Study: NCT06564974
Drug: Vamorolone
Normalized name: Vamorolone
DrugBank: Vamorolone (DB15114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on treatment with Vamorolone (AGAMREE®) Dosage: Oral Suspension: 40 mg/mL . Per package insert, the recommended dosage is 6 mg/kg taken orally once daily, up to a maximum daily dosage of 300 mg for patients weighing more than 50 kg.~Decrease dosage gradually when administered for more than one week.
Study: NCT06144788
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT 1/2 dual inhibitor
Study: NCT05851456
Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
Normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT06106789
Drug: Tobramycin inhalation solution
Normalized name: Tobramycin Inhalation Solution
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin Inhalation Solution is a yellowish clear liquid, the main ingredient is tobramycin.~Antimicrobial non-nebulized inhalation preparation according to the current clinical situation, mainly polymyxin, amikacin, depending on the specific circumstances of each hospital.
Study: NCT05414201
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous Injection
Study: NCT05350774
Drug: IV normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV normal saline 250ml for 5 days
Study: NCT04933149
Drug: Ketamine Infustion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
Study: NCT05853965
Drug: Belantamab mafodotin, Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belantamab mafodotin (IV) Venetoclax (PO)
Study: NCT04586231
Drug: Belzutifan
Normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release 40 mg tablet
Study: NCT04586231
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsule available in 4 mg and 10 mg dosages
Study: NCT04586231
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet available in 20 mg, 40 mg and 60 mg dosages
Study: NCT04741464
Drug: Tinzaparin
Normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin 20 000 anti-Xa IU/mL dispensed in graduated syringes of 0.5 mL, 0.7 mL and 0.9 mL at the dose of 175IU/Kg/d.~Strategy: Tinzaparin 175 UI/Kg/d for 21 days After this time the physician will continue the treatment of his choice to treat DVT.
Study: NCT05913583
Drug: Immune checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1.
Study: NCT04868981
Drug: GST-HG141 tablets
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
Study: NCT05757869
Drug: Milvexian
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian will be administered orally.
Study: NCT05195450
Drug: Tenofovir alafenamide fumarate
Normalized name: Tenofovir Alafenamide fumarate
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: • TAF 25 mg OD vs no treatment x 5 years and beyond
Study: NCT05648318
Drug: Lactulose oral solution
Normalized name: lactulose Oral Solution
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the LOS group, patients were instructed to drink 200ml lactulose (Duphalac, Olst, the Netherlands; 200ml/bottle) diluted with clear water into 1L 4-6h before colonoscopy at a rate of 250ml every 30min.
Study: NCT05648318
Drug: PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient in the PEG group were instructed to drink 2L of PEG (each liter containing 59g PEG 4000, 1.46g sodium chloride, 5.68g sodium sulfate, 0.74g potassium chloride, 1.68g sodium bicarbonate; WanHe Pharmaceutical Co, Ltd., China) 4-6h before colonoscopy at a rate of 250ml every 15min
Study: NCT05757869
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban will be administered orally.
Study: NCT05757869
Drug: Apixaban Placebo
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban matching apixaban placebo will be administered orally.
Study: NCT04891757
Drug: Low Dose Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LDAC administered subcutaneously (SC)
Study: NCT04891757
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine administered intravenously
Study: NCT05838560
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
Study: NCT05838560
Drug: quercetin
Normalized name: Quercetin
DrugBank: Quercetin (DB04216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined.
Study: NCT06270836
Drug: Tarcocimab
Normalized name: Tarcocimab tedromer
DrugBank: Tarcocimab tedromer (DB18937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection
Study: NCT05470504
Drug: Pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30 mg subcutaneously every day for 4 weeks.
Study: NCT05316155
Drug: Erdafitinib Intravesical Delivery System
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erdafitinib intravesical delivery system will be administered.
Study: NCT06442462
Drug: SPG302
Normalized name: SPG302
DrugBank: SPG302 (DB18103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: small synthetic molecule
Study: NCT05286008
Drug: Ropivacaine at high concentration
Normalized name: AT-7519
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before the induction of anesthesia,0.375% ropivacaine is used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study: NCT05286008
Drug: Ropivacaine and dexamethasone
Normalized name: dexamethasone and antibiotics
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before the induction of anesthesia, 0.375% Ropivacaine and 5.0mg dexamethasone are used for bilateral transversus abdominis plane block in a volume of 20 mL of each side
Study: NCT05215418
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
Study: NCT05215418
Drug: Phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentermine 30 mg capsule
Study: NCT05393271
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will be administered
Study: NCT06312748
Drug: L-Citrulline
Normalized name: L-citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg tablet
Study: NCT06312748
Drug: BH4
Normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10mg/kg
Study: NCT06312748
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg tablet
Study: NCT06312748
Drug: Placebo for Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin-matched Placebo
Study: NCT04356638
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Midazolam and intranasal placebo
Study: NCT04356638
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal Dexmedetomidine and oral placebo
Study: NCT05250973
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered subcutaneously.
Study: NCT05250973
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered by SC injection or IV.
Study: NCT05250973
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered orally or IV.
Study: NCT06178614
Drug: JNJ-87890387
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-87890387 will be administered.
Study: NCT06154226
Drug: Pantoprazole
Normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive pantoprazole (40 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on post operative day 1 (POD 1) for a total of 4 doses over 2 days.
Study: NCT06154226
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive famotidine (20 mg iv q12H) for 2 days perioperatively (first dose after anesthesia induction and before surgical incision, second dose at chest closure, then followed by 2 doses daily (Q12hr dosing) on POD 1 for a total of 4 doses over 2 days.
Study: NCT06093893
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mcg/kg will be administered intravenously over 10 minutes; followed by maintenance infusion of 0.2 to 1 mcg/kg/hour.
Study: NCT06093893
Drug: Nicardipine
Normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg will be administered intravenously and increase by 0.5-1 mg if the initial dose is ineffective, to a maximum of 15 mg / hour or